Transcontinental Atypical Femoral Fracture Consortium (TrAFFiC)

Welcome to the TrAFFiC Study website.

The TrAFFiC Study is investigating risk factors and identifying causes of atypical femoral fractures to find ways to prevent it.

Atypical femoral fractures are rare and atypical thigh-bone fractures that have been associated with anti-osteoporosis medications that inhibit bone breakdown. The causes of these fractures are not yet known. If we can understand what factors lead to the development of these fractures, we can try to prevent them. Nevertheless, the benefits of anti-osteoporosis medications to reduce broken bones due to osteoporosis far outweigh the small risk of an atypical femur fracture.

The TrAFFiC study is a multi-center international study that has been approved by Human Research Ethics Committees at each study site. We are investigating clinical and genetic factors that may be involved in the development of these atypical femoral fractures.

If you are a patient who has had an atypical femoral fracture or a clinician who would like to participate in the TrAFFiC Study, please contact us for more information.

You can read more about the TrAFFiC Study here or contact the lead researcher: Professor Peter R Ebeling via +61 3 8572 2570; peter.ebeling@monash.edu


  • Royal North Shore Hospital

    Researcher: A/Prof Rory Clifton-Bligh

  • National University of Singapore

    Researcher: Dr Alvin Ng

    Researcher: Dr Tet Sun Howe

  • Kaiser Permanente Southern California

    Researcher: Dr Annette Adams

    Researcher: Dr Richard Dell


Partners

Monash University
Monash Health Translational Precinct
Erasmus University Medical Centre

Affiliates

Monash Health
Austin Health
Alfred Health
Western Health